ProTECT III is a clinical study designed to see if progesterone, a naturally occurring hormone found in our bodies, is effective in decreasing disability after traumatic brain injury (TBI). Multiple animal studies suggest that progesterone given after TBI results in less brain damage; and, two pilot studies have shown that progesterone is safe and that it may reduce disability when given to patients early after TBI.  The ProTECT III study will further test these findings to find out if progesterone with standard care works better than standard care alone to reduce damage from TBI. Since patients are often severely impaired and the treatment needs to be started quickly, ProTECT III is being conducted as an exception from informed consent for emergency research study. Prior to starting the study, we need your input! Please learn more and provide your opinion about the potential risks and benefits of conducting this study in your community.
Link to this page http://www.philanett.com/protect

JavaScript is disabled!
To display this content, you need a JavaScript capable browser.

Doctors have long been searching for a way to treat brain injury.  A new study at Temple University is looking at whether a hormone we already have in the body can help prevent permanent disability.  Dr. Nina Gentile of Temple's School of Medicine says that when the head is injured, the brain swells.  Damaged cells die and healthy cells get squeezed and flooded with toxic byproducts.  Pilot data has shown that progesterone, a naturally occurring hormone, can reduce the swelling of the brain to almost nothing, while stimulating growth and repair. Gentile, who's leading the local trials, says that with more than a million brain injuries a year, there is a desperate need for new treatments. "If we can make even a small benefit for these people, it
will be tremendous," she said.

JavaScript is disabled!
To display this content, you need a JavaScript capable browser.